Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy

07:55 EST 23 Jan 2018 | Xconomy

Two therapies from the emerging field of engineered T cells won FDA approval to treat blood cancers last year, and the scramble is on to treat more types of cancer. Led by Usman “Oz” Azam (pictured above), the executive who once led Novartis’s cell and gene therapy group, Tmunity Therapeutics aims to be a big […]

Original Article: Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy


More From BioPortfolio on "Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...